trending Market Intelligence /marketintelligence/en/news-insights/trending/hYJHQKP_eiZJVnYkdQGNPg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Arsanis, X4 Pharmaceuticals complete all-share merger

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Arsanis, X4 Pharmaceuticals complete all-share merger

Arsanis Inc. completed its all-share merger transaction with X4 Pharmaceuticals Inc.

Waltham, Mass.-based Arsanis issued 0.5702 of a common share in exchange for each share of X4 Pharmaceuticals.

The combined company will be named X4 Pharmaceuticals and will be headquartered in Cambridge, Mass. It will start trading on the Nasdaq Capital Market under the symbol XFOR on March 14.

The president and CEO of X4 Pharmaceuticals, Paula Ragan, and Adam Mostafa, X4 Pharmaceuticals' CFO, will lead the combined company. The board of the combined company has six members, with four directors from the former board of X4 Pharmaceuticals and two directors from the previous board of Arsanis.

Michael Wyzga will serve as the new chairman of the board.

Arsanis is also implementing a 1-for-6 reverse stock split following the merger on March 13 and will pay cash for any fractional shares resulting from the reverse split. The combined company will have about 6.7 million shares outstanding after the reverse stock split.